Medartis Holding AG (MED) AI Stock Analysis

• Market Cap: CHF1.06B
• Dividend Yield: N/A
• Average Volume (3M): 6.38K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: 7.29%
• EPS Growth: -112.70%
• Country: CH
• Employees: 816
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.03
• Shares Outstanding: 13,618,142
• 10 Day Avg. Volume: 7,172
• 30 Day Avg. Volume: 6,381
• PEG Ratio: 0.44
• Price to Book (P/B): 2.60
• Price to Sales (P/S): 3.12
• P/FCF Ratio: 33.36
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF90.00
• Price Target Upside: 20.81% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: CHF77.00 ▲(3.36% Upside)

Medartis Holding AG's strong financial performance is overshadowed by bearish technical indicators and poor valuation metrics. The stock's technical analysis suggests potential downside risk, while the valuation indicates overvaluation concerns. The company's financial stability and improved cash flow are positive, but operational efficiency needs enhancement to improve profitability.

Positive Factors

Revenue Growth

Consistent revenue growth indicates effective market penetration and product adoption, supporting long-term business expansion and stability.

Cash Flow Improvement

Significant improvement in cash flow reflects efficient capital management, enhancing the company's ability to invest in growth and innovation.

Balance Sheet Health

A strong balance sheet with manageable debt levels ensures financial stability and flexibility for future strategic initiatives.

Negative Factors

Low Net Profit Margin

A low net profit margin suggests challenges in cost management, which could hinder profitability and limit reinvestment capacity.

Operational Efficiency

Moderate operational margins indicate room for improvement in efficiency, which is crucial for enhancing profitability and competitive positioning.

Return on Equity

A modest return on equity suggests potential underutilization of shareholder funds, which could impact investor confidence and capital allocation.

Medartis Holding AG Business Overview & Revenue Model

Company Description

Medartis Holding AG is a Swiss-based medical technology company focused on the development, manufacturing, and marketing of innovative orthopedic and neurosurgical implants and instruments. The company specializes in the fields of bone fracture management and cranio-maxillofacial surgery, offering a wide range of products designed to improve patient outcomes. Medartis operates primarily in the orthopedic and trauma sectors, providing solutions that enhance surgical precision and recovery.

How the Company Makes Money

Medartis generates revenue primarily through the sale of its orthopedic and neurosurgical implants and instruments. Key revenue streams include direct sales of surgical products to hospitals and clinics, as well as distribution agreements with medical device partners. The company benefits from ongoing partnerships with healthcare providers and organizations that facilitate the adoption of its products in surgical procedures. Additionally, Medartis invests in research and development to innovate and expand its product offerings, which can lead to increased market share and revenue growth. The company's focus on high-quality, specialized medical solutions allows it to command premium pricing, further contributing to its financial performance.

Medartis Holding AG Financial Statement Overview

Summary

Medartis Holding AG shows strong revenue growth and a robust gross profit margin. However, the net profit margin is low, indicating challenges in cost management. The balance sheet is healthy with a strong equity ratio and manageable debt levels. Cash flow has improved significantly, highlighting efficient capital management.

Income Statement

Medartis Holding AG demonstrates a strong revenue growth trajectory with a 6% increase from 2023 to 2024. The gross profit margin has remained robust at approximately 79.5% in 2024. However, the net profit margin remains relatively low at 1.57%, indicating potential challenges in cost management or operational efficiency. The EBIT and EBITDA margins are moderate at 3.5% and 13.4% respectively, showing room for improvement in operational leverage.

Balance Sheet

The company maintains a healthy balance sheet with a favorable equity ratio of 58.6% in 2024, indicating a strong capital structure. The debt-to-equity ratio is at a manageable 0.45, reflecting prudent financial leverage. Return on equity is modest at 1.31%, suggesting potential underutilization of shareholder funds. Overall, the financial position is stable with potential for enhanced returns.

Cash Flow

Medartis Holding AG exhibits a significant improvement in free cash flow, growing from CHF 1.17 million in 2023 to CHF 21 million in 2024. The operating cash flow to net income ratio is strong, highlighting efficient cash conversion from profits. The free cash flow to net income ratio is robust at 5.95, underscoring efficient capital management. However, consistent positive cash flow generation remains critical for sustained financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	236.34M	224.83M	212.01M	182.82M	159.88M	127.65M
Gross Profit	186.96M	178.68M	167.57M	135.39M	121.57M	93.89M
EBITDA	35.38M	30.18M	24.69M	15.64M	26.10M	13.96M
Net Income	-487.00K	3.53M	619.00K	-5.78M	6.84M	-943.57K
Balance Sheet
Total Assets	465.70M	459.96M	349.53M	327.89M	298.18M	282.79M
Cash, Cash Equivalents and Short-Term Investments	120.51M	138.69M	25.20M	20.60M	82.64M	82.73M
Total Debt	123.88M	121.23M	27.39M	27.96M	24.07M	27.18M
Total Liabilities	204.50M	190.31M	94.58M	90.11M	74.18M	69.76M
Stockholders Equity	261.21M	269.65M	254.96M	237.78M	224.00M	213.04M
Cash Flow
Free Cash Flow	19.47M	21.00M	5.05M	-22.72M	10.57M	-455.29K
Operating Cash Flow	27.49M	28.17M	19.96M	-3.93M	20.95M	12.61M
Investing Cash Flow	-24.29M	-19.06M	-37.83M	-52.91M	-15.87M	-22.86M
Financing Cash Flow	-7.70M	100.58M	23.21M	-3.90M	-4.78M	-4.73M

Medartis Holding AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 74.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MED, the sentiment is Negative. The current price of 74.5 is below the 20-day moving average (MA) of 77.79, below the 50-day MA of 83.57, and below the 200-day MA of 78.46, indicating a bearish trend. The MACD of -2.31 indicates Negative momentum. The RSI at 36.69 is Neutral, neither overbought nor oversold. The STOCH value of 32.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:MED.

Medartis Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSLN	73 Outperform	CHF568.22M	7.80	―	―	58.51%	―
MOVE	71 Outperform	$2.97B	33.09	23.83%	0.45%	16.59%	65.76%
SOON	65 Neutral	CHF12.41B	23.78	―	2.17%	3.79%	-7.84%
SFZN	63 Neutral	$3.43B	21.56	15.79%	0.51%	0.77%	16.70%
TECN	62 Neutral	CHF1.80B	28.26	4.57%	2.14%	-9.34%	-37.50%
MED	54 Neutral	CHF1.06B	-1,989.80	―	―	7.29%	-112.70%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Medartis Holding AG Corporate Events

Medartis Reports Strong Growth and Raises Sales Forecast for 2025

Medartis Holding AG reported a significant organic sales growth of 15.3% in the first half of 2025, driven by strong performance in the EMEA and USA regions. The company raised its sales forecast for the full year, reflecting confidence in its strategic initiatives, including the integration of NeoOrtho and KeriMedical, and the upcoming launch of its flagship product TOUCH in the USA. Despite challenges such as CHF appreciation and US tariffs, Medartis maintained a stable core EBITDA margin. The company’s efforts to strengthen its competitive position in the USA and Latin America, along with investments in R&D and digital offerings, are expected to drive future growth.

The most recent analyst rating on (CH:MED) stock is a Buy with a CHF86.00 price target. To see the full list of analyst forecasts on Medartis Holding AG stock, see the CH:MED Stock Forecast page.